Symptomatic and neuroprotective effects of A2A receptor antagonists in Parkinson's disease

Adenosine: A Key Link between Metabolism and Brain Activity

Volumn 9781461439035, Issue , 2013, Pages 361-384

  Pinna, Annalisa ^a,b   Simola, Nicola ^a   Frau, Lucia ^a   Morelli, Micaela ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

6 hydroxydopamine; Basal ganglia; Caudate putamen; Clinical trials; Dopamine D2 receptor; Dyskinesia; l DOPA; MPTP; Tremor; Urate

Indexed keywords

EID: 84886952444     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3903-5_18     Document Type: Chapter

References (113)

1. Adair TH (2005) Growth regulation of the vascular system: An emerging role for adenosine. Am J Physiol Regul Integr Comp Physiol 289:R283-R296
2. Al fi nito PD, Wang SP, Manzino L, Rijhsinghani S, Zeevalk GD, Sonsalla PK (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. J Neurosci 23:10982-10987
3. Alonso A, Rodríguez LA, Logroscino G, Hernán MA (2007) Gout and risk of Parkinson disease: A prospective study. Neurology 69:1696-1700
4. Annanmaki T, Pessala-Driver A, Hokkanen L, Murros K (2008) Uric acid associates with cognition in Parkinson's disease. Parkinsonism Relat Disord 14:576-578
5. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
6. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB et al (2009) Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 66:1460-1468
7. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN (2003) Adenosine A (2A) receptor antagonist treatment of Parkinson's disease. Neurology 61:293-296
8. Bibbiani F, Oh JD, Petzer JP, Castagnoli N Jr, Chen JF, Schwarzschild MA, Chase TN (2003) A 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184:285-294
9. Black KJ, Campbell MC, Dickerson W, Creech ML, Koller JM, Chung S, Bandak SI (2010) A randomized, double-blind, placebo-controlled cross-over trial of the adenosine A 2A antagonist SYN115 in Parkinson disease. Neurology 74(Suppl 2):A317
10. Bové J, Serrats J, Mengod G, Cortés R, Tolosa E, Marin C (2005) Neuroprotection induced by the adenosine A 2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res 165:362-374
11. Bové J, Serrats J, Mengod G, Cortés R, Aguilar E, Marin C (2006) Reversion of levodopa-induced motor fl uctuations by the A 2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats. Synapse 59:435-444
12. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
13. Brooks DJ, Warrington S, Tendolkar A, Cutler DL, Hunter J (2009) Positron emission tomography (PET) study of preladenant in healthy male subjects. Mov Disord 24(suppl 1):S257
14. Brooks DJ, Papapetropoulos S, Vandenhende F, Tomic D, He P, Coppell A, O'Neill G (2010) An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 33:55-60
15. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A 2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127:1075-1084
16. Camarasa J, Pubill D, Escubedo E (2006) Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res 1111:72-82
17. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F et al (2007) Striatal adenosine A 2A and cannabinoid CB 1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32:2249-2259
18. Carta AR, Pinna A, Cauli O, Morelli M (2002) Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-DOPA and A 2A receptor blockade plus L-DOPA in dopamine-denervated rats. Synapse 44:166-174
19. Carta AR, Fenu S, Pala P, Tronci E, Morelli M (2003) Selective modi fi cations in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. Eur J Neurosci 18:2563-2572
20. Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M (2009) Inactivation of neuronal forebrain A 2A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem 111:1478-1489
21. Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD (2003) Translating A 2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 61:S107-S111
22. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA (1999) A (2A) adenosine receptor de fi ciency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200
23. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ et al (2001a) The role of the D (2) dopamine receptor (D (2) R) in A (2A) adenosine receptor (A (2A) R)-mediated behavioral and cellular responses as revealed by A (2A) and D (2) receptor knockout mice. Proc Natl Acad Sci USA 98:1970-1975
24. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001b) Neuroprotection by caffeine and A (2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
25. Church WH, Ward VL (1994) Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res Bull 33:419-425
26. Cipriani S, Chen X, Schwarzschild MA (2010) Urate: A novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 4:701-712
27. Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J et al (2006) Presynaptic control of striatal glutamatergic neurotransmission by adenosine A 1-A 2A receptor heteromers. J Neurosci 26:2080-2087
28. Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A 2A and metabotropic glutamate mGlu5 receptors increase their ef fi cacy in reversing Parkinsonian de fi cits in rats. Neuropsychopharmacology 29:1451-1461
29. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909
30. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, Sun Z, Sampson AR et al (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9:251-259
31. De Vera M, Rahman MM, Rankin J, Kopec J, Gao X, Choi H (2008) Gout and the risk of Parkinson's disease: A cohort study. Arthritis Rheum 59:1549-1554
32. Derlet RW, Tseng JC, Albertson TE (1992) Potentiation of cocaine and d-amphetamine toxicity with caffeine. Am J Emerg Med 10:211-216
33. Deussen A, Brand M, Pexa A, Weichsel J (2006) Metabolic coronary fl ow regulation-current concepts. Basic Res Cardiol 101:453-464
34. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A 2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A 2A receptor knockout mice. Br J Pharmacol 134:68-77
35. Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, Sussman NM (2010) A long-term study of istradefylline in subjects with fl uctuating Parkinson's disease. Parkinsonism Relat Disord 16:423-426
36. Fenu S, Pinna A, Ongini E, Morelli M (1997) Adenosine A 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147
37. Fenu S, Wardas J, Morelli M (2009) Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol 20:363-379
38. Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM (2010) Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 16:16-20
39. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482-487
40. Ferré S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casadó V, Fuxe K, Goldberg SR, Lluis C et al (2002) Synergistic interaction between adenosine A 2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci USA 99:11940-11945
41. Frau L, Borsini F, Wardas J, Khairnar AS, Schintu N, Morelli M (2011) Neuroprotective and anti-in fl ammatory effects of the adenosine A (2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse 65:181-188
42. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51(1):83-133
43. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A (2008) Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol 167:831-838
44. Gevaerd MS, Takahashi RN, Silveira R, Da Cunha C (2001) Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res Bull 55:101-106
45. Giménez-Llort L, Schiffmann SN, Shmidt T, Canela L, Camón L, Wassholm M, Canals M, Terasmaa A, Fernández-Teruel A, Tobeña A et al (2007) Working memory de fi cits in transgenic rats overexpressing human adenosine A 2A receptors in the brain. Neurobiol Learn Mem 87:42-56
46. Grondin R, Bédard PJ, Hadj Tahar A, Grégoire L, Mori A, Kase H (1999) Antiparkinsonian effect of a new selective adenosine A 2A receptor antagonist in MPTP-treated monkeys. Neurology 52:1673-1677
47. Hauser RA, Shulman LM, Trugman JM, Roberts J, Mori A, Ballerini R, Sussman NM (2008) Study of istradefylline in patients with Parkinson's disease on levodopa with motor fl uctuations. Mov Disord 23:2177-2185
48. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson's disease and motor fl uctuations: A phase 2, doubleblind, randomised trial. Lancet Neurol 10:221-229
49. Hersh fi eld MS (2005) New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunode fi ciency associated with adenosine deaminase de fi ciency. Eur J Immunol 35:25-30
50. Hettinger BD, Lee A, Linden J, Rosin DL (2001) Ultrastructural localization of adenosine A 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 431:331-346
51. Higgins GA, Grzelak ME, Pond AJ, Cohen-Williams ME, Hodgson RA, Varty GB (2007) The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A 2A receptors. Behav Brain Res 185:32-42
52. Higley MJ, Sabatini BL (2010) Competitive regulation of synaptic Ca 2+ in fl ux by D 2 dopamine and A 2A adenosine receptors. Nat Neurosci 13:958-966
53. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J et al (2002) Coaggregation, cointernalization, and codesensitization of adenosine A 2A receptors and dopamine D 2 receptors. J Biol Chem 77:18091-18097
54. Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, Cohen-Williams ME, Higgins GA, Impagnatiello F, Nicolussi E et al (2009) Characterization of the potent and highly selective A 2A receptor antagonists preladenant and SCH 412348 in rodent models of movement disorders and depression. J Pharmacol Exp Ther 330:294-303
55. Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, Pond AJ, Hadjtahar A, Belanger N, Gregoire L et al (2010) Preladenant, a selective A (2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 225:384-390
56. Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O (2005) Adenosine A 2A, but not A 1, receptors mediate the arousal effect of caffeine. Nat Neurosci 8:858-859
57. Hunot S, Hirsch EC (2003) Neuroin fl ammatory processes in Parkinson's disease. Ann Neurol 53:S49-S58
58. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y (2002) Neuroprotection by adenosine A 2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 80:262-270
59. Jellinger KA (2002) Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 62:347-376
60. Jenner P (2005) Istradefylline, a novel adenosine A 2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 14:729-738
61. Jenner P, Marsden CD (1986) The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J Neural Transm Suppl 20:11-39
62. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA (2005) Interactions between metabotropic glutamate 5 and adenosine A 2A receptors in normal and parkinsonian mice. J Neurosci 25:10414-10419
63. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998a) Adenosine A 2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
64. Kanda T, Tashiro T, Kuwana Y, Jenner P (1998b) Adenosine A 2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport 9:2857-2860
65. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A (2A) antagonist KW-6002 with L-DOPA or with selective D 1 or D 2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTPtreated monkeys. Exp Neurol 162:321-327
66. Kerschensteiner M, Meinl E, Hohlfeld R (2009) Neuro-immune crosstalk in CNS diseases. Neuroscience 158:1122-1132
67. Khairnar A, Plumitallo A, Frau L, Schintu N, Morelli M (2010) Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res 17:435-439
68. Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T (2007) Interactions between 3,4-methylenedioxymethamphetamine, methamphetamine, ketamine, and caffeine in human intestinal Caco-2 cells and in oral administration to rats. Forensic Sci Int 170:183-188
69. Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease Exp Neurol 197:284-290
70. Lange KW, Riederer P (1994) Glutamatergic drugs in Parkinson's disease. Life Sci 55: 2067-2075
71. Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE, Winsky-Sommerer R, Semba K, Fredholm BB, Boison D, Hayaishi O, Urade Y, Chen JF (2011) Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci 6:10067-10075
72. LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM (2008) Adenosine A 2A receptor antagonist istradefylline (KW-6002) reduces OFF time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63:295-302
73. Lopes LV, Cunha RA, Ribeiro JA (1999) Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J Neurophysiol 82:3196-3203
74. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M (2004) Cutting edge: physiologic attenuation of proin fl ammatory transcription by the Gs protein-coupled A 2A adenosine receptor in vivo. J Immunol 173:21-24
75. Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A 2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 84:1398-1410
76. Masino SA, Dulla CG (2005) Adenosine, glutamate and pH: interactions and implications. Neurol Res 27:149-152
77. McNamara R, Kerans A, O'Neill B, Harkin A (2006) Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology 50:69-80
78. McNamara R, Maginn M, Harkin A (2007) Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration. Eur J Pharmacol 555:194-198
79. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M (2010) Clinical ef fi cacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study. Mov Disord 25:1437-1443
80. Morelli M, Carta AR, Kachroo A, Schwarzschild MA (2010) Pathophysiological roles for purines: Adenosine, caffeine and urate. Prog Brain Res 183:183-208
81. Nishi A, Liu F, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P (2003) Metabotropic mGlu5 receptors regulate adenosine A 2A receptor signaling. Proc Natl Acad Sci USA 100:1322-1327
82. O'Neill M, Brown VJ (2006) The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) 184:46-55
83. Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW (2000) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23:S8-S19
84. Oh JD, Chase TN (2002) Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 23:133-139
85. Ohta A, Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of in fl ammation and protection from tissue damage. Nature 414:916-920
86. Pierri M, Vaudano E, Sager T, Englund U (2005) KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 48:517-524
87. Pinna A (2009) Novel investigational adenosine A 2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs 18:1619-1631
88. Pinna A, Di Chiara G, Wardas J, Morelli M (1996) Blockade of A 2A adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D 1 agonists in dopamine-denervated rats. Eur J Neurosci 8:1176-1181
89. Pinna A, Fenu S, Morelli M (2001) Motor stimulant effects of the adenosine A 2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopaminelesioned rats. Synapse 39:233-238
90. Pinna A, Volpini R, Cristalli G, Morelli M (2005) New adenosine A 2A receptor antagonists: Actions on Parkinson's disease models. Eur J Pharmacol 512:157-164
91. Pinna A, Pontis S, Morelli M (2006) Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is in fl uenced by the testing environment. Behav Brain Res 171:175-178
92. Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M (2010) A new ethyladenine antagonist of adenosine A (2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology 58:613-623
93. Popoli P, Minghetti L, Tebano MT, Pintor A, Domenici MR, Massotti M (2004) Adenosine A 2A receptor antagonism and neuroprotection: mechanisms, lights, and shadows. Crit Rev Neurobiol 16:99-106
94. Quarta D, Ferré S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR (2004) Opposite modulatory roles for adenosine A 1 and A 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens: effects of chronic caffeine exposure. J Neurochem 88:1151-1158
95. Ritchie K, Carrière I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69:536-545
96. Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P (2006) The novel adenosine A 2A receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. Eur J Pharmacol 546:82-87
97. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD et al (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679
98. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: A model of parkinsonian tremor. Prog Neurobiol 56:591-611
99. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007) Adenosine A 2A receptors and basal ganglia physiology. Prog Neurobiol 83:277-292
100. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Parkinson Study Group PRECEPT Investigators et al (2008) Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 65:716-723
101. Shah U, Hodgson R (2010) Recent progress in the discovery of adenosine A (2A) receptor antagonists for the treatment of Parkinson's disease. Curr Opin Drug Discov Devel 13:466-480
102. Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M (2004) Blockade of adenosine A 2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on speci fi c striatal regions. Exp Neurol 189:182-188
103. Soriano A, Ventura R, Molero A, Hoen R, Casadó V, Cortés A, Fanelli F, Albericio F, Lluís C, Franco R et al (2009) Adenosine A 2A receptor-antagonist/dopamine D 2 receptor-agonist bivalent ligands as pharmacological tools to detect A 2A-D 2 receptor heteromers. J Med Chem 52:5590-5602
104. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, Sussman NM (2008) A 12-week, placebocontrolled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 70:2233-2240
105. Stasi MA, Borsini F, Varani K, Vincenzi F, Di Cesare MA, Minetti P, Ghirardi O, Carminati P (2006) ST 1535: A preferential A 2A adenosine receptor antagonist. Int J Neuropsychopharmacol 9:575-584
106. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: A review of animal studies. Front Biosci 13:2614-2632
107. Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M (2007) Characterization of the antiparkinsonian effects of the new adenosine A 2A receptor antagonist ST1535: Acute and subchronic studies in rats. Eur J Pharmacol 566:94-102
108. Vanattou-Saïfoudine N, Gossen A, Harkin A, Neuropsychopharmacology Research Group (2011) A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release. Eur J Pharmacol 650:220-228
109. Wang JH, Ma YY, van den Buuse M (2006) Improved spatial recognition memory in mice lacking adenosine A 2A receptors. Exp Neurol 199:438-445
110. Wang XJ, Luo WF, Wang LJ, Mao CJ, Wang L, Liu CF (2009) Study on uric acid and the related factors associated with cognition in the patients with Parkinson's disease. Zhonghua Yi Xue Za Zhi 89:1633-1635
111. Wardas J, Konieczny J, Lorenc-Koci E (2001) SCH 58261, an A (2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse 41:160-171
112. Wei CJ, Singer P, Coelho J, Boison D, Feldon J, Yee BK, Chen JF (2011) Selective inactivation of adenosine A( 2A ) receptors in striatal neurons enhances working memory and reversal learning. Learn Mem 18:459-474
113. Yu L, Shen HY, Coelho JE, Araújo IM, Huang QY, Day YJ, Rebola N, Canas PM, Rapp EK, Ferrara J et al (2008) Adenosine A 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346